No they technically don’t, but the meeting also discussed the ‘Adult’ aGVHD trial progression and not just the Paeds aGVHD data and BLA.
I am keen to receive an update on the FDA’s thoughts on MSB’s methodology and progression of the trial. It also may give us more confirmation about MSB’s assay approach and FDA’s ongoing thoughts here.
If you know what I mean.
No they technically don’t, but the meeting also discussed the...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.04 |
Change
0.010(0.98%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.03 | $1.04 | $1.02 | $858.9K | 835.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 27774 | $1.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.04 | 131878 | 19 |
View Market Depth
| Last trade - 10.42am 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.03 |
Change
0.010 ( 0.42 %) |
||||
| Open | High | Low | Volume | ||
| $1.03 | $1.04 | $1.02 | 126708 | ||
| Last updated 11.00am 17/05/2024 ? | |||||
| MSB (ASX) Chart |